Anthony Rothschild, MD, a professor at the Irving S. and Betty Brudnick Endowed Chair of Psychiatry, University of Massachusetts Medical School, says that many primary care physicians feel more comfortable prescribing newer anti-depressant drugs with fewer side effects.
Anthony Rothschild, MD, a professor at the Irving S. and Betty Brudnick Endowed Chair of Psychiatry, University of Massachusetts Medical School, says that many primary care physicians feel more comfortable prescribing newer anti-depressant drugs with fewer side effects.
He adds that patients who are diagnosed with depression for the 1st time are often done so by their primary care physician. This is because he or she may not have believed they were suffering from depression and would not have previously considered contacting a psychiatrist. Physicians are in a “unique position” to diagnose patients with depression and to prescribe an anti-depressant drug regimen.
However, Dr Rothschild explains that there are certain types of depression that should not be handled by primary care physicians alone. He recommends that primary care physicians refer patients who suffer from conditions such as psychotic depression or bipolar disorder to a psychiatrist, as they can be more complicated.
“It’s not unusual for me to see patients with depression who may have had 1 trial of an anti-depressant from their primary care physician,” Dr Rothschild says. “If it works out, I don’t ever see them. But, if it doesn’t work out then and it becomes a little more complicated, then the primary care doctor will refer the patient to a psychiatrist.”
Dr Rothschild also serves as director at the UMass Medical Depression Center and Center for Psychopharmacologic Research and Treatment, and as a program director at the Mood Disorders Comprehensive Consultation Clinic at UMass Memorial Medical Center.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More